Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
5.41
+0.28 (5.46%)
Mar 9, 2026, 4:00 PM EDT - Market closed
Iovance Biotherapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | -390.98 | -372.18 | -444.04 | -395.89 | -342.25 | Upgrade
|
| Depreciation & Amortization | 47.32 | 48.07 | 33.13 | 21.14 | 13.98 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.04 | 1.79 | - | - | - | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | - | 0.4 | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -7.2 | -10.26 | -3.61 | 0.47 | 6.01 | Upgrade
|
| Stock-Based Compensation | 61.58 | 109.63 | 62.63 | 84.02 | 69.77 | Upgrade
|
| Other Operating Activities | 11.1 | -3 | -3.41 | - | - | Upgrade
|
| Change in Accounts Receivable | -13.11 | -69.19 | -0.15 | - | - | Upgrade
|
| Change in Inventory | -14.21 | -44.38 | -10.12 | - | - | Upgrade
|
| Change in Accounts Payable | -6.66 | -7.84 | 4.83 | 5.88 | 6.98 | Upgrade
|
| Change in Other Net Operating Assets | 9.71 | -5.61 | -1.08 | -8.78 | 17.58 | Upgrade
|
| Operating Cash Flow | -302.41 | -352.98 | -361.82 | -292.76 | -227.94 | Upgrade
|
| Capital Expenditures | -33.84 | -11.07 | -22.29 | -20.43 | -37.57 | Upgrade
|
| Cash Acquisitions | - | -52.57 | -212.63 | - | - | Upgrade
|
| Investment in Securities | 81.33 | -32.77 | 79.68 | 276.88 | 37.71 | Upgrade
|
| Investing Cash Flow | 47.5 | -96.41 | -155.24 | 256.46 | 0.13 | Upgrade
|
| Long-Term Debt Issued | - | - | - | - | 1 | Upgrade
|
| Net Debt Issued (Repaid) | - | - | - | - | 1 | Upgrade
|
| Issuance of Common Stock | 307.83 | 403.52 | 465.75 | 192.8 | 238.27 | Upgrade
|
| Repurchase of Common Stock | -7.06 | -12.86 | -2.8 | -2.65 | - | Upgrade
|
| Financing Cash Flow | 300.77 | 390.66 | 462.96 | 190.15 | 239.27 | Upgrade
|
| Foreign Exchange Rate Adjustments | 1.14 | -0.54 | -2.74 | - | - | Upgrade
|
| Net Cash Flow | 47.01 | -59.27 | -56.84 | 153.85 | 11.46 | Upgrade
|
| Free Cash Flow | -336.24 | -364.05 | -384.11 | -313.18 | -265.52 | Upgrade
|
| Free Cash Flow Margin | -127.61% | -221.89% | -32305.30% | - | - | Upgrade
|
| Free Cash Flow Per Share | -0.94 | -1.26 | -1.63 | -1.97 | -1.73 | Upgrade
|
| Levered Free Cash Flow | -162.42 | -198.76 | -211.47 | -173.54 | -129.35 | Upgrade
|
| Unlevered Free Cash Flow | -162.42 | -198.76 | -211.47 | -173.54 | -129.35 | Upgrade
|
| Change in Working Capital | -24.27 | -127.02 | -6.52 | -2.89 | 24.55 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.